<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; attributed</title>
	<atom:link href="http://www.tapanray.in/tag/attributed/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Should high prices of new drugs, causing low access to majority of patients, be attributed to high R&amp;D cost?</title>
		<link>http://www.tapanray.in/should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost</link>
		<comments>http://www.tapanray.in/should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost/#comments</comments>
		<pubDate>Mon, 13 Feb 2012 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[attributed]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[causing]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[majority]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=134</guid>
		<description><![CDATA[Many thought leaders have been arguing since long that pharmaceutical R&#38;D expenses are being over stated and the real cost is much less. An article titled “Demythologizing the high costs of pharmaceutical research”, published by the London School of Economics &#8230; <a href="http://www.tapanray.in/should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
